Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Impact of Pain on Depression Treatment Response in Primary Care

Impact of Pain on Depression Treatment Response in Primary Care MATTHEW J. BAIR,MD, MS,REBECCA L. ROBINSON, MS, GEORGE J. ECKERT, MAS, PAUL E. STANG,PHD, THOMAS W. CROGHAN,MD, AND KURT KROENKE,MD Objective: Pain commonly coexists with depression, but its impact on treatment outcomes has not been well studied. Therefore, we prospectively evaluated the impact of comorbid pain on depression treatment response and health-related quality of life. Methods: We analyzed data from the ARTIST study, a randomized controlled trial with naturalistic follow-up conducted in 37 primary care clinics. Participants were 573 clinically depressed patients randomized to one of three selective serotonin reuptake inhibitor (SSRI) antidepressants: fluoxetine, paroxetine, or sertraline. Depression as assessed by the Symptom Checklist-20 (SCL-20) was the primary outcome. Secondary outcomes included pain and health-related quality of life. Results: Pain was reported by more than two thirds of depressed patients at baseline, with the severity of pain mild in 25% of patients, moderate in 30%, and severe in 14%. After 3 months of antidepressant therapy, 24% of patients had a poor depression treatment response (ie, SCL-20 1.3). Multivariate odds ratios for poor treatment response were 1.5 (95% confidence interval, 0.8 –3.2) for mild pain, 2.0 (1.1– 4.0) for moderate pain, and 4.1 (1.9 – 8.8) for severe pain compared http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychosomatic Medicine Wolters Kluwer Health

Impact of Pain on Depression Treatment Response in Primary Care

Kroenke, Kurt
Psychosomatic Medicine , Volume 66 (1) – Jan 1, 2004
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/impact-of-pain-on-depression-treatment-response-in-primary-care-P0oCObYpfM

References (40)

ISSN
0033-3174
eISSN
1534-7796
DOI
10.1097/01.PSY.0000106883.94059.C5
Publisher site
See Article on Publisher Site

Abstract

MATTHEW J. BAIR,MD, MS,REBECCA L. ROBINSON, MS, GEORGE J. ECKERT, MAS, PAUL E. STANG,PHD, THOMAS W. CROGHAN,MD, AND KURT KROENKE,MD Objective: Pain commonly coexists with depression, but its impact on treatment outcomes has not been well studied. Therefore, we prospectively evaluated the impact of comorbid pain on depression treatment response and health-related quality of life. Methods: We analyzed data from the ARTIST study, a randomized controlled trial with naturalistic follow-up conducted in 37 primary care clinics. Participants were 573 clinically depressed patients randomized to one of three selective serotonin reuptake inhibitor (SSRI) antidepressants: fluoxetine, paroxetine, or sertraline. Depression as assessed by the Symptom Checklist-20 (SCL-20) was the primary outcome. Secondary outcomes included pain and health-related quality of life. Results: Pain was reported by more than two thirds of depressed patients at baseline, with the severity of pain mild in 25% of patients, moderate in 30%, and severe in 14%. After 3 months of antidepressant therapy, 24% of patients had a poor depression treatment response (ie, SCL-20 1.3). Multivariate odds ratios for poor treatment response were 1.5 (95% confidence interval, 0.8 –3.2) for mild pain, 2.0 (1.1– 4.0) for moderate pain, and 4.1 (1.9 – 8.8) for severe pain compared

Journal

Psychosomatic Medicine – Wolters Kluwer Health

Published: Jan 1, 2004

There are no references for this article.